Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00178971 · ClinicalTrials.gov registry record · Phase 3
Serotonin 1A Agonists and Cognition in Schizophrenia
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 60
- Enrollment target
NCT00178971 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 60 participants.
The verdict
NCT00178971, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 60 participants
- Enrollment target
Study Summary
Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory and problem-solving ability will be tested before and after medication.
Interventions
- DRUG placebo
- DRUG adjunctive treatment with buspirone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00178971
The ClinicalTrials.gov registry entry for NCT00178971 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00178971 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00178971 about?
NCT00178971 is a clinical study titled "Serotonin 1A Agonists and Cognition in Schizophrenia". Examines cognitive functioning in patients with schizophrenia or schizoaffective disorder who have been treated with antipsychotic medications. Patients will be assigned to take active medication (Buspar)or placebo along with their prescribed antipsychotic medication for six weeks. Patients' memory ...
What is the current status of trial NCT00178971?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 60 participants. The study started on 2003-01. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00178971?
The interventions under investigation include: placebo (DRUG), adjunctive treatment with buspirone (DRUG).
Who is sponsoring clinical trial NCT00178971?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.